Zevra Therapeutics, Inc. (ZVRA) Misses Q3 EPS by 10c

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) reported Q3 EPS of ($0.40), $0.10 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $2.89 million versus the consensus estimate of $3.38 million.

For earnings history and earnings-related data on Zevra Therapeutics, Inc. (ZVRA) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Brinker Int'l (EAT) PT Lowered to $240 at DA Davidson Ahead of Analyst Day
• Kroger (KR) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY27 EPS Guidance